FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

ValueSets, Realm US

14,182 resources

Source: Text:

By Version

By Authority

  • none: 1,981
  • hl7: 12,201

 

Start Prev Rows 2800 - 3000 Next

PackageVersionIdentityName/TitleStatusFMMWGDateAuthSource(s)
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.816.jsonRubella (Tests for rubella virus IgG Antibody [Ratio] in Serum)active2024-01hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.818.jsonMeasles (Tests for measles virus IgG Antibody [Ratio] in Serum)active2025-03hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.820.jsonRubella (Tests for rubella virus IgG Antibody [Quantitative] in Serum)active2024-01hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.822.jsonPneumoconiosis (Unspecified) (ICD10CM)active2023-06hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.823.jsonPneumoconiosis (Unspecified) (SNOMED)active2023-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.824.jsonComputerized Tomography of Chest (Imaging)active2023-01hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.830.jsonPoliovirus Infection (Tests for Poliovirus Antibody Titer in Serum Specimen)active2025-02hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.835.jsonLead in Blood (Disorders) (ICD10CM)active2023-01hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.836.jsonLead in Blood (Disorders) (SNOMED)active2023-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.839.jsonAcid Fast Bacilli (Organism or Substance in Lab Results)active2023-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.841.jsonTuberculosis (Interferon Gamma Release Assays)active2024-01hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.842.jsonTests by Microscopic Observation in Tissueactive2024-06hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.846.jsonSARS (Tests for SARS_CoV by Culture and Identification Method)active2024-01hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.847.jsonSARS (Tests for SARS_CoV Nucleic Acid)active2024-01hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.86.jsonHemolytic Uremic Syndrome (HUS) (Disorders) (SNOMED)active2025-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.864.jsonNausea (SNOMED)active2023-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.865.jsonConfusion (SNOMED)active2023-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.867.jsonDyspnea (SNOMED)active2023-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.869.jsonLoss of Consciousness (SNOMED)active2024-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.87.jsonThrombotic Thrombocytopenic Purpura (TTP) (SNOMED)active2024-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.875.jsonSARS (Organism or Substance in Lab Results)active2024-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.878.jsonMERS (Tests for MERS_CoV Nucleic Acid)active2023-01hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.88.jsonHemolytic Uremic Syndrome (HUS) (Disorders) (ICD10CM)active2024-06hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.881.jsonDifficulty Breathing (SNOMED)active2023-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.884.jsonTests by Microscopic Observation in Bloodactive2025-02hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.889.jsonHantavirus Infection (Tests for Hantavirus IgM IgG Total Antibody)active2025-02hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.892.jsonOrganisms (Tests by Microscopic Observation in Tissue by Acid Fast Stain)active2024-06hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.895.jsonRhinorrhea (SNOMED)active2024-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.896.jsonTests by Microscopic Observation in Blood Smearactive2023-01hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.897.jsonDengue Virus Infection (Test Panels for dengue virus IgM IgG Antibody)active2025-02hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.9.jsonXray of Chest (Imaging)active2024-06hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.90.jsonCough (ICD10CM)active2023-01hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.902.jsonAcute Renal Failure [Unspecified Cause] (ICD10CM)active2024-06hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.907.jsonArthritis [Unspecified Cause] (SNOMED)active2025-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.91.jsonCough (SNOMED)active2023-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.910.jsonEpididymitis [Unspecified Cause] (SNOMED)active2023-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.911.jsonEpididymitis [Unspecified Cause] (ICD10CM)active2023-01hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.914.jsonOsteomyelitis [Unspecified Cause] (SNOMED)active2024-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.915.jsonOsteomyelitis [Unspecified Cause] (ICD10CM)active2023-01hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.918.jsonSpondylitis [Unspecified Cause] (SNOMED)active2025-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.919.jsonArthritis [Unspecified Cause] (ICD10CM)active2023-06hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.92.jsonThrombotic Thrombocytopenic Purpura (TTP) (ICD10CM)active2023-01hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.927.jsonThrombocytopenia [Unspecified Cause] (ICD10CM)active2023-01hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.928.jsonBleeding [Unspecified Cause] (SNOMED)active2024-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.930.jsonECG Abnormalities [Unspecified Cause] (SNOMED)active2024-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.931.jsonHematemesis [Unspecified Cause] (SNOMED)active2024-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.932.jsonHematemesis [Unspecified Cause] (ICD10CM)active2024-01hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.934.jsonHematuria [Unspecified Cause] (SNOMED)active2024-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.935.jsonHemoptysis (SNOMED)active2024-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.937.jsonGastrointestinal Hemorrhage [Unspecified Cause] (SNOMED)active2024-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.942.jsonPetechiae [Non Traumatic] (SNOMED)active2024-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.952.jsonThrombocytopenia [Unspecified Cause] (SNOMED)active2024-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.956.jsonSepsis [Septicemia] [Bacterial] [Unspecified Organism] (SNOMED)active2024-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.957.jsonRegional Lymphadenitis [Including Bubo] (SNOMED)active2025-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.958.jsonRegional Lymphadenitis (ICD10CM)active2023-06hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.965.jsonProteinuria [Unspecified Cause] (ICD10CM)active2023-06hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.969.jsonProteinuria [Unspecified Cause] (SNOMED)active2024-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.970.jsonBulbar Weakness (SNOMED)active2024-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.971.jsonBulbar Weakness (ICD10CM)active2024-06hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.976.jsonDysphagia (SNOMED)active2025-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.978.jsonImpaired Respiration [Unspecified Cause] (SNOMED)active2024-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.979.jsonBotulism (Organism or Substance in Lab Results)active2024-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.98.jsonShigellosis (Disorders) (SNOMED)active2024-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.989.jsonTests for Mycobacterium species by Culture and Identification Methodactive2025-02hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.994.jsonOrganisms (Tests for Nucleic Acid)active2023-01hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.998.jsonShigellosis (Tests for Enteroinvasive E. coli Nucleic Acid)active2025-02hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1146.999.jsonChlamydia species (Organism or Substance in Lab Results)active2023-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.109.jsonPressure Injury Stage 2, 3, 4 or Unstageableactive2023-02hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.110.jsonPressure Injury Stage 2, 3, 4 or Unstageableactive2024-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.112.jsonPressure Injury Deep Tissueactive2024-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.113.jsonPressure Injury Stage 2, 3, 4 or Unstageableactive2022-04hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.122.jsonInpatient Fallsactive2021-06hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.130.jsonAnticoagulants for VTE Prophylaxisactive2025-02hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.131.jsonAnticoagulants for Indications Other than VTE Prophylaxisactive2024-01hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.160.jsonAbdominal or Pelvic CT Scan with Contrastactive2024-06hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.163.jsonUltrasound of Lower Extremitiesactive2024-08hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.164.jsonUltrasound of Lower Extremitiesactive2024-08hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.165.jsonUltrasound of Lower Extremitiesactive2024-08hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.171.jsonInpatient Fallsactive2021-06hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.183.jsonAnti Factor Xa Assayactive2024-06hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.187.jsonExtracorporeal Membrane Oxygenation (ECMO)active2022-04hl7cms
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.188.jsonExtracorporeal Membrane Oxygenation (ECMO)active2022-04hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.190.jsonIntra Aortic Balloon Pumpactive2022-04hl7cms
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.191.jsonIntra Aortic Balloon Pumpactive2022-04hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.193.jsonResuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)active2022-04hl7cms
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.194.jsonPressure Injury Deep Tissue Diagnosesactive2022-04hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.196.jsonPressure Injury Stage 2, 3, 4, or Unstageable Diagnosesactive2022-04hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.197.jsonPresent on Admission or Clinically Undeterminedactive2022-04hl7cms
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1147.198.jsonNot Present On Admission or Documentation Insufficient to Determineactive2022-04hl7cms
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.1.jsonDEXA Dual Energy Xray Absorptiometry, Bone Densityactive2016-07hl7cpt
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.11.jsonBladder Cancer Staging Ta for Urology Careactive2016-07hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.12.jsonBladder Cancer staging T1 for Urology Careactive2024-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.13.jsonBladder Cancer staging Tis for Urology Careactive2024-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.15.jsonCarcinoma of urinary bladder, superficialactive2016-07hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.16.jsonInjection Leuprolide Acetateactive2017-08hl7cms
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.17.jsonHigh grade bladder cancer Ta for Urology Careactive2017-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.18.jsonImmunocompromised state for Urology Careactive2017-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.19.jsonSystemic chemotherapy for urology careactive2017-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.2.jsonBladder Cancer in Situactive2016-07hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.20.jsonCorticosteroids for patients receiving Urology Careactive2017-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.21.jsonCalcineurin inhibitors for patients receiving Urology Careactive2017-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.23.jsonImmunomodulators for patients undergoing Urology Careactive2017-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.24.jsonMonoclonal antibody for patient undergoing Urology Careactive2017-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.28.jsonRadiotherapy for patients undergoing Urology Careactive2017-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.29.jsonPlasmacytoid cell, morphologic abnormality for urology careactive2017-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.3.jsonBladder Cancer in Situactive2024-02hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.30.jsonSarcomatoid, morphologic abnormality for Urology Careactive2017-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.31.jsonMicropapillary, morphologic abnormality, for Urology Careactive2017-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.32.jsonImmunosuppressive Drugs for Urology Careactive2024-02hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.38.jsonDEXA Dual Energy Xray Absorptiometry, Bone Density for Urology Careactive2017-08hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.39.jsonMixed histology urothelial cell carcinoma for Urology Careactive2023-02hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.4.jsonBCG Bacillus Calmette Guerin, Ticeactive2016-07hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.40.jsonCystectomy for Urology Careactive2017-03hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.44.jsonUnavailability of Bacillus Calmette Guerin for urology careactive2017-03hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.45.jsonBladder Cancer for Urology Careactive2017-03hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.48.jsonAndrogen deprivation therapy for Urology Careactive2021-02hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.5.jsonBCG Bacillus Calmette Guerin, Connaughtactive2016-07hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.52.jsonBCG Bacillus Calmette Guerin for Urology Careactive2020-02hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.53.jsonCystectomy for Urology Careactive2018-04hl7cpt
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.54.jsonAcute Tuberculosis for Urology Careactive2018-04hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.55.jsonCystectomy for Urology Careactive2022-03hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.56.jsonActive Tuberculosis for Urology Careactive2018-04hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.57.jsonBladder Cancer Staging Tis for Urology Careactive2019-07hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.58.jsonBladder Cancer Staging Tis for Urology Careactive2019-07hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.59.jsonHospital Services for Urologyactive2023-02hl7cpt
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.6.jsonPeripheral DXA Scanactive2016-07hl7cpt
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.60.jsonChemotherapy Agents for Advanced Canceractive2024-02hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.8.jsonTuberculosis Diagnosis Prior to Urology Careactive2016-07hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1151.9.jsonLeukemia Diagnosis Prior to Urology Careactive2016-07hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.13.jsonPreventative Clinical Encountersactive2025-03hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.14.jsonIntensive Lifestyle Interventionsactive2023-01hl7cpt
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.15.jsonIntensive Lifestyle Interventionsactive2023-01hl7cms
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.16.jsonIntensive Lifestyle Interventionsactive2023-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.17.jsonIntensive lifestyle interventionsactive2023-01hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.21.jsonOutpatient Clinical Encountersactive2025-03hl7cpt
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.22.jsonOutpatient Clinical Encountersactive2025-03hl7cms
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.23.jsonOutpatient Clinical Encountersactive2025-03hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.24.jsonOutpatient Clinical Encountersactive2025-03hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.25.jsonReason for No Intensive Lifestyle Interventionactive2023-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.27.jsonType 2 Diabetes Diagnosesactive2023-01hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.28.jsonType 2 Diabetes Diagnosesactive2023-01hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.29.jsonType 2 Diabetes Diagnosesactive2023-01hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.30.jsonPrediabetes HbA1c Testsactive2023-01hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.31.jsonPrediabetes HbA1c Testsactive2023-01hl7cpt
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.32.jsonPrediabetes HbA1c Testsactive2023-01hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.33.jsonPrediabetes Oral Glucose Tolerance Testsactive2023-01hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.34.jsonPrediabetes Oral Glucose Tolerance Testsactive2023-01hl7cpt
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.35.jsonPrediabetes Oral Glucose Tolerance Testsactive2023-01hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.36.jsonPrediabetes Fasting plasma glucose or Plasma Glucose Testsactive2023-01hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.37.jsonPrediabetes Fasting plasma glucose or Plasma Glucose Testsactive2023-01hl7cpt
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.38.jsonPrediabetes Fasting plasma glucose or Plasma Glucose Testsactive2023-01hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.4.jsonGlycemic Screening Testsactive2025-03hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.40.jsonSickle Cell Disease with Vaso Occlusive Episodeactive2024-05hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.41.jsonSickle Cell Disease with Vaso Occlusive Episodeactive2024-05hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.42.jsonSickle Cell Disease with Vaso Occlusive Episodeactive2024-05hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.43.jsonAnalgesics for Acute Painactive2025-02hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.49.jsonMedication Therapy Management Services for Essential Hypertensionactive2024-10hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.5.jsonGlycemic Screening Testsactive2023-01hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.52.jsonRemote Physiologic Blood Pressure Monitoringactive2024-10hl7cpt
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.57.jsonAldosterone Receptor Blocker for Hypertensionactive2024-10hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.58.jsonAlpha Blocker for Hypertensionactive2024-10hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.59.jsonAngiotensin Converting Enzyme Inhibitor for Hypertensionactive2024-10hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.6.jsonGlycemic Screening Testsactive2023-01hl7cpt
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.60.jsonAngiotensin II Receptor Blocker for Hypertensionactive2024-10hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.61.jsonBeta Blocker for Hypertensionactive2024-10hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.62.jsonCalcium Channel Blocker Dihydropyridine for Hypertensionactive2024-10hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.63.jsonCalcium Channel Blocker Non Dihydropyridine for Hypertensionactive2024-10hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.64.jsonCentral Acting for Hypertensionactive2024-10hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.65.jsonDirect Renin Inhibitor for Hypertensionactive2024-10hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.66.jsonLoop Diuretic for Hypertensionactive2024-10hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.67.jsonNeuronal Blocking Agent for Hypertensionactive2024-10hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.68.jsonPotassium Sparing Diuretic for Hypertensionactive2024-10hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.69.jsonThiazide Diuretic for Hypertensionactive2024-10hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.7.jsonPreventative Clinical Encountersactive2025-03hl7cpt
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.70.jsonVasodilator for Hypertensionactive2024-10hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.73.jsonAnalgesics for Acute Pain (Non Parenteral Route)active2025-02hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.74.jsonAnalgesics for Acute Pain (Parenteral Route)active2025-02hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.75.jsonAnalgesics for Acute Pain Non Oral Enteral/Mucosal Routesactive2024-11hl7rx
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.77.jsonAntihypertensive Medication Classesactive2024-10hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.78.jsonMedication Therapy Management Services for Essential Hypertensionactive2024-10hl7cpt
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.79.jsonMedication Therapy Management Services for Essential Hypertensionactive2024-10hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.8.jsonPreventative Clinical Encountersactive2025-03hl7cms
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.84.jsonRenal Colicactive2025-04hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.85.jsonRenal Colicactive2025-04hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.86.jsonRenal Colicactive2025-04hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.88.jsonDirect LDL Cholesterolactive2025-05hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.89.jsonCalculated LDL Cholesterolactive2025-05hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1160.9.jsonPreventative Clinical Encountersactive2025-03hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1164.50.jsonUrinary retentionactive2017-10hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1164.51.jsonUrinary retentionactive2017-06hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1164.52.jsonUrinary retentionactive2017-06hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1164.65.jsonMorbid Obesityactive2018-04hl7icd
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1164.66.jsonMorbid Obesityactive2018-04hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1164.67.jsonMorbid Obesityactive2018-04hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1164.68.jsonBMI greater than 40active2019-02hl7loinc
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1164.69.jsonMorbid Obesityactive2019-02hl7vsac
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1166.141.jsonContraceptive Patch SNOMED Devicesactive2021-10hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1166.143.jsonLive Birth Delivery CPT Proceduresactive2024-09hl7cpt
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1166.144.jsonContraceptive Patch SNOMED Provision Proceduresactive2021-10hl7sct
us.nlm.vsacR4ValueSet-2.16.840.1.113762.1.4.1166.145.jsonContraceptive Patch SNOMED Findingsactive2021-10hl7sct